Effects of Sucralfate on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Healthy Volunteers
Authors:
- 1 January 2001
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (Supplement) , 49-55
Abstract
To investigate the effect of concomitant Al3+ (sucralfate) administration on the pharmacokinetics and tolerability of moxifloxacin. This was a single-centre, randomised, nonblinded, 2-way crossover study in healthy volunteers. 12 healthy men (age 21 to 41 years) were enrolled in the study. The plasma and urinary pharmacokinetics of moxifloxacin were characterised up to 72 hours after single doses of moxifloxacin 400mg administered orally either alone or together with 190mg of Al3+ (Sucralfat-Ratiopharm® 1000) given immediately before and at 5, 10, 15 and 24 hours after the dose of moxifloxacin. There was a 2-week washout phase between the treatments. The treatments were well tolerated. The concomitant administration of Al3+ reduced the bioavailability of moxifloxacin [geometric mean area under the concentration-time curve from zero to infinity (AUC∞) 12.9 versus 32.2 mg/L · h; relative bioavailability 40%, 90% confidence interval (CI) 33 to 49%] and slowed down the absorption rate [median time to maximum concentration (tmax) 3.5 versus 1.0 hours], with a reduction of the maximum plasma concentration (Cmax) [geometric mean Cmax0.82 versus 2.83 mg/L; estimated true ratio of Cmax 29%, 90% CI 20 to 42%]. Concomitant ingestion with sucralfate and/or oral Al3+-containing antacids significantly reduces the bioavailability of moxifloxacin. This is compatible with reduced solubilisation as a consequence of a chelation reaction with polyvalent cations, a common finding for quinolones. Therefore, staggered administration of moxifloxacin and Al3+-containing or related cationic interactants should be considered to avoid a loss of therapeutic efficacy due to subtherapeutic plasma concentrations of the quinolone.Keywords
This publication has 24 references indexed in Scilit:
- Evaluation of the Influence of Antacids and H2 Antagonists on the Absorption of Moxifloxacin after Oral Administration of a 400mg Dose to Healthy VolunteersClinical Pharmacokinetics, 2001
- Effect of Calcium Supplements on the Oral Bioavailability of Moxifloxacin in Healthy Male VolunteersClinical Pharmacokinetics, 2001
- Absolute bioavailability of moxifloxacinClinical Therapeutics, 1999
- Absorption Interactions With Fluoroquinolones 1995 UpdateDrug Safety, 1995
- The effect of food on the interaction of ofloxacin with sucralfate in healthy volunteersEuropean Journal of Clinical Pharmacology, 1994
- Effect of sucralfate on absorption of norfloxacin and ofloxacinAntimicrobial Agents and Chemotherapy, 1994
- FluoroquinolonesDrugs, 1993
- Drug interactions with quinolonesJournal of Antimicrobial Chemotherapy, 1990
- Drug Interactions with QuinolonesClinical Infectious Diseases, 1989
- Inhibition of enoxacin absorption by antacids or ranitidineAntimicrobial Agents and Chemotherapy, 1989